Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02951598 · ClinicalTrials.gov registry record
A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD)
A clinical trial of Alzheimer Disease and Mild Cognitive Impairment, sponsored by Eli Lilly and Company.
- Active
- Registry status
- 1,400
- Enrollment target
- 20
- Study locations
NCT02951598: Active study of Alzheimer Disease and Mild Cognitive Impairment, sponsored by Eli Lilly and Company.
NCT02951598 is a study of Alzheimer Disease and Mild Cognitive Impairment that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 1,400 participants, below the 2,746-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (49% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02951598, a study of Alzheimer Disease and Mild Cognitive Impairment, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- 1,400 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to learn about health care use, costs, and clinical outcomes over time for amyloid positive participants with early stages of AD in the United States. This study is for research purposes only, and is not intended to treat any medical condition. No study therapy(ies) for AD will be administered.
Conditions Studied
Interventions
- DRUG Florbetapir F 18 PET Scan
Study Locations (20)
California
- California Pharmaceutical Research Institute - Anaheim
- Advanced Research Center - Anaheim
- Sun Valley Research Center - Imperial
- Global Clinical Trials - Irvine
- Irvine Clinical Research Center - Irvine
- Alliance Research Centers - Laguna Hills
- Pacific Clinical Studies, Inc - Los Alamitos
- California Neurological Services, Inc. - Panorama City
- Havana Research Institute - Pasadena
- Clinical Innovations, Inc. - Riverside
- Breakthrough Clinical Trials - San Bernardino
- HB Clinical Trials - Santa Ana
- Ventura Clinical Trials - Ventura
Florida
- JEM Research Institute - Atlantis
- Visionary Investigators Network - Aventura
- Research Alliance - Clearwater
- Clinical Research of South Florida - Coral Gables
- Infinite Clinical Research - Doral
Colorado
- Colorado Neurological Institute - Englewood
Connecticut
- Coastal Connecticut Research, LLC - New London
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,400 participants |
| Start Date | 2016-10-29 |
| Est. Completion | 2026-04-28 |
What the registry record for NCT02951598 still lists
NCT02951598 is an observational study that tracks outcomes without assigning an intervention. Its 1,400 participants enrollment target places it among the larger protocols in the corpus, below the 2,746-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (49% lower).
The record links to 2 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which Florbetapir F 18 PET Scan is the first listed.
NCT02951598 names 20 study sites across 4 states, led by California, Florida, Colorado.
Frequently Asked Questions
What is clinical trial NCT02951598 about?
NCT02951598 is a clinical study titled "A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD)". The purpose of this study is to learn about health care use, costs, and clinical outcomes over time for amyloid positive participants with early stages of AD in the United States. This study is for research purposes only, and is not intended to treat any medical condition. No study therapy(ies) for ...
What is the current status of trial NCT02951598?
This trial is currently active not recruiting. The enrollment target is 1,400 participants. The study started on 2016-10-29. Estimated completion is 2026-04-28.
What conditions does trial NCT02951598 study?
This clinical trial studies the following conditions: Alzheimer Disease, Mild Cognitive Impairment.
What interventions are being tested in trial NCT02951598?
The interventions under investigation include: Florbetapir F 18 PET Scan (DRUG).
Who is sponsoring clinical trial NCT02951598?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02951598 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02951598's enrollment target sits among peer trials
1,400 28th of 306 higher than 279 of 306 other Alzheimer Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
RECRUITING · Phase 3
-
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
RECRUITING · Phase 4
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms
RECRUITING · NA
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Cognitive Neurology Unit Clinical Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02205762 · 1,400 participants · Phase 2
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
- NCT02445222 · 1,400 participants · Phase 3
CAR-T Long Term Follow Up (LTFU) Study
- NCT03145077 · 1,400 participants · NA
Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Diagnosing Osteoradionecrosis in Patients With Head and Neck Cancer That Is Primary, Has Come Back, or Has Spread to Other Places in the Body
- NCT04250857 · 1,400 participants
HeartStart FRx Defibrillator Event Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI